Thanks for the board skinny.
--You welcome.
Sorry for barging in on the thread, but I felt the news I brought with me re: 60 minutes paid for the cover.
--Thanks for bringing news re: 60 min. News from JCC is known and at least 6 months old, for some of as here on SI. Only this time with more press/TV coverage. Not a bad things, but why now? I give SUGN big credence for keeping things strait during ENMD/BLSI angiogenesis/cancer hype (last 9 months). I would not like to change this now.
I am unable to provide credence to claim of non-toxicity.
--SU101 has side effects. But not an-tolerable.
Not all angiogenesis drugs will work.
--Which one will, which will not? So, we all can get rich in next few years!
Thought rock in my head. Fears of bad TV press? This least concern, compared to ATP. You mean like BMY and ENMD?
--No, no fear from TV press. SU5416 efficiency in some cancer type is for real.
Isn't the cure for 1 specific cancer a great place to start?
--Not yet cure, but Rosen sounded like it is *cure*, OK more like *as very promising combination*. However, if you read JCC news carefully, it is not colon cancer itself what they are targeting. It is metastatic spread and growth at other organs like liver, kidney,...Also, some other research institutions contribute to SU5416 valuation as cancer therapy.
I also like GZMO (they have a mystery angiogenesis drug licensed from Folkman, antisense, p53, and a lot of other things - like money!)
--GZMO licensed protein isn't mystery. I am keeping GZMO in my screen, but do not have position.
Miljenko |
